President Donald Trump unveiled the Great Healthcare Plan to lower drug costs and insurance premiums, but healthcare executives say the proposal lacks sufficient detail to assess whether it would meaningfully reduce costs.
Mark Cuban warned that many employers are collecting drug rebate money funded by their sick employees — a practice that can violate fiduciary duties under ERISA. His company, Cost Plus Drugs, is partnering with organizations like Humana’s CenterWell to create direct-to-employer programs that bypass PBMs and deliver medications at lower net prices.
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
It's a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain.
It’s critical that healthcare organizations delivering on the program’s promise not be torpedoed by the “bad actors”
In an interview, Rabah talked about the promise of AI, where it can have the most impact, while also responding to the IRA and high drug prices in the United States.
Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
How are employers tackling the current landscape of healthcare costs? We turned to Shawn Gremminger, CEO of the National Alliance of Healthcare Purchaser Coalitions, a group of regional coalitions representing self-insured employers large and small that cover roughly 40 million people.
Experts from BRG recently discussed the two presidential candidates' stances on key healthcare issues, including drug pricing, Medicaid and AI.
If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California.
Months before the FTC sued the three largest pharmacy benefit managers, the CEO of Blue Shield of California battled its PBM - CVS Caremark - to bring a lower cost prostate cancer drug to its members.
How to turn analytics into actual policy outcomes.
The industry is increasingly under attack by lawmakers from both parties for drug prices most Americans regard as unreasonable, so the election outcome could be pivotal to drug companies’ fortunes.
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.